More than 150 of Bristol Myers Squibb's employees will cycle in seven European countries from 3-20 September in support of the Union for International Cancer Control (UICC) and selected members to raise funds with the aim of accelerating the fight against cancer and facilitating a better life for cancer patients.
The nearly 3,000 km long ride will take the cyclists through Germany, Switzerland, Italy, France, Spain, Belgium and the United Kingdom.
Eight teams will relay each other and feature riders from 14 countries including Belgium, Denmark, Finland, Sweden, Norway, France, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, Ireland and the United Kingdom.
The goal of C2C4C is to raise awareness for cancer research and European cancer organisations that are members of the UICC.
"We are extremely grateful for the ongoing support from Bristol Myers Squibb and the employees who will be taking on this challenge. After a difficult time during the pandemic, this unique fundraising initiative will benefit not only our members but many cancer patients around the world. Big thank you to BMS for all their support and trust in our mission, said Dr Cary Adams, CEO of the Union for International Cancer Control."
The participants are novice riders who have committed themselves to 5 months of intensive training to complete their portion of the ride. Some are cancer survivors, others have witnessed the devastating impact of cancer on friends and family. All are dedicated Bristol Myers Squibb employees who are highly motivated to support the fight against cancer.
The previous edition of the Country 2 Country 4 Cancer ride had to be postponed due to the COVID-19 pandemic in 2020, yet BMS still donated all funds raised to UICC member organisations.
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.